CN101045079A - Extractive of Rabdosia rubescens having anti AIDS virus function and its application - Google Patents
Extractive of Rabdosia rubescens having anti AIDS virus function and its application Download PDFInfo
- Publication number
- CN101045079A CN101045079A CN 200610025274 CN200610025274A CN101045079A CN 101045079 A CN101045079 A CN 101045079A CN 200610025274 CN200610025274 CN 200610025274 CN 200610025274 A CN200610025274 A CN 200610025274A CN 101045079 A CN101045079 A CN 101045079A
- Authority
- CN
- China
- Prior art keywords
- dbs
- polysaccharide
- rabdosia rubescens
- extract
- effective site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An anti-HIV extract is prepared from blushred rabdosia herb through extracting in water, depositing in alcohol to obtain polyose DBS-40, DBS-60, DBS-70, DBS-80 and DBS-90, and dialyzing the DBS-70 by dialysis bag 36DM to obtain polyose DBS-70-6 which contains rhamnose, arabinose, galactose and glucose. Its application in preparing the medicines for preventing and treating AIDS is also disclosed.
Description
Technical field
The present invention relates to the AIDS preventing and controlling medicine, be specifically related to have HIV (human immunodeficiency virus) and suppress active natural plants medicament extract, relate more specifically to the active site of Rabdosia rubescens extract anti AIDS virus.
Technical background
Acquired immune deficiency syndrome (AIDS) is a kind of human health to be caused the infectious disease of significant damage by what its etiology HIV (human immunodeficiency virus) (HIV) caused, claim again century incurable disease.Now know together, fundamentally prevent and treat acquired immune deficiency syndrome (AIDS), vaccine is a best choice.An ideal vaccine should be wide spectrum, efficient, low toxicity, inexpensive.Yet because variation of the height of HIV (human immunodeficiency virus) and powerful escape function make the research of vaccine become very difficult, in foreseeable future, such vaccine will be succeedd and be also had very long road to walk.Therefore the research of anti-hiv drug and to make it invest market service be a very urgent task in the patient of infective virus.
Up to now, announce that by U.S. FDA the anti-hiv drug of official listing is 23, comprise three types: a, viral reverse transcriptase inhibitor; The inhibitor of b, virus protease; C, blocking-up cell and the viral small peptide (table 1 vides infra) that merges.
Table 1 antiretroviral drugs
| A. viral reverse transcriptase inhibitor non-nucleoside reverse transcriptase inhibitor (NNRTIs) delavirdine (Rescriptor) Yi Feiweilun (Sustiva) nevirapine (nevirapine amune) nucleoside/nucleoside reverse transcriptase inhibitor (NRTIs) A Bukawei (Ziagen) A Bukawei+lamivudine+zidovudine (Trizivir) didanosine (Videx, ddI) Emtricitabine (Emtriva, FTC) lamivudine (Epivir, 3TC) lamivudine+zidovudine (Combivir) stavudine (Zerit, D4T) Tenofovir DF (Viread) zalcitabine (HIVID ddC) zidovudine (azidothymidine AZT, AZT, ZDV) | B. protease inhibitors (Pis) amprenavir (Agenerase) Atazanavir (Reyataz) indinavir (Crixivan) Lopinavir+ Ritonavir (Kaletra) nelfinavir (viracept see nelfinaivr) Ritonavir (Norvir) kills Kui Nawei-sgc (Fortovase, inverase) |
| C. merge and inhibitor Enfuvirtide (Fuzeon, T-20) |
Other has more than 30 a new drug candidate respectively at clinical I, II, the III phase develop in (table 2).
Anti-HIV new medicament thing in table 2 exploitation
| Medicine | Classification | Clinical stages | Company |
| ACH-126; 444 (Beta-L-Fd4C) ADA (azodicarboamide) Atazanavir (BMS-232623) BMS-806 Calanolide A Capavirine Coviracil (emtricitabine; FTC) DAPD (amdoxovir) DPC 083 DPC, 817 Hydrea (hydroxycarbamide) L870810 Peptide T PRO 542 S-1360 SCH-C T-20 T-1249 are for Pune Wei TMC 114 TMC 125 UK-427,857 VX-175/GW433908 | NRTI zinc refers to inhibitor protein enzyme inhibitor Entry inhibitor NNRTI NNRTI NRTI NRTI NNRTI NRTI cell factor inhibitors integrase inhibitor Entry inhibitor Entry inhibitor integrase inhibitor Entry inhibitor Entry inhibitor Entry inhibitor protease inhibitors protease inhibitors NNRTI Entry inhibitor protease inhibitors | The I phase I/II phase III phase I phase I/II phase II/III phase III phase II phase II phase I/II phase II/III phase I phase II phase II phase I/II phase I phase III phase I/II phase II phase II phase II phase I phase III phase | Achillion Hubriphar Bristol-Myers Squibb Bristol-Myers Squibb Sarawak MediChem Plizer/Agouron Triangle (going on the market) Triangle Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Merck Georgetown University Progenics Shionog Schering-Plough Trimeris/Roche (going on the market) Trimeris/Roche Boehringer IngeIhem Tibotec-Virco Tibotec-Virco Pfizer Vertex/GlaxoSmithKline |
The experience of clinical application shows that the application of single medicine is easy to virus is produced drug resistance.Select the invention of the highly active antiretroviral therapy (HAART) (being commonly called as " HAART ") that different classes of medicine makes up for use and be used in the morbidity process of having alleviated the patient to a great extent according to patient's symptom, improve quality of the life, prolonged life.Therefore, enlarging selectable new drug battle array is to guarantee therapeutic quality and the new task that faces.Data (these documents and data are all introduced this description as a reference) referring to following document and website:
1.Johnston ML:HIV/AIDS vaccine development---challenge, progressive and following direction, Reviews in Medical Virology, 6 (3): 123-140,1996.
2.www.ARAS.AB.CA/haart.html
3.www.hivandhepatitis.com
4.www.fdg.gov
Usually new drug of exploitation needs 8～10 years to listing, and fund reaches more than one hundred million dollars.Generally speaking, the annual Zai $8 of a patient's medicine cost, 000～12, between 000, individual drug even Gao Da $15,000～20,000.This is difficult to bear to most of general patient, concerning the patient of developing country, is difficult to especially enjoy especially.Like this, other wards off new footpath, and the original new drug of seeking a suitable developing country is same urgent and important.From the extract of natural plant the screening anti-HIV active ingredient or effective site, make it finally become new drug, be one may with feasible road.Simultaneously also opened up a new road for the research in this field.
The present inventor is once by the test of external anti AIDS virus, screens to have HIV (human immunodeficiency virus) and suppress active Rabdosia rubescens from a large amount of natural plants.Rabdosia rubescens be labiate crack rice fork (
Rabdosia Rubescens (Hemsl.) Hara) dry aerial parts.Summer, Qiu Erji tap, and dry.This product stem is square column type, long 80～70cm, and the surface red brown has pubescence; Matter is hard, section light green or yellow-white.Page or leaf has handle to life; Leaf-shrinkage is avette or width egg shape after the flattening, long 6.5～13cm, wide 3～6cm; Tip is point gradually, and the wide wedge shape of base portion, section shape or near heart-shaped are extended down to handle under suddenly contracting, and there is the rough sawn tooth at the edge; Upper surface is green brown, and the gland point is arranged, and the lower surface green is draped over one's shoulders thin pubescence along vein.Give birth on sympodium panicle top, spends for a short time, and the calyx tubular is bell, 5 fissures, corolla two lips.The wide obovate of pyrene, the top does not have hair.Feeble QI perfume (or spice), bitter in the mouth, sweet is slightly cold.Has heat-clearing and toxic substances removing, the promoting blood circulation and stopping pain effect.Be used for laryngopharynx swelling and pain, tonsillitis, snake bite and insect sting (one one of Chinese Pharmacopoeia, 1977 editions).
Data shows, the Rabdosia rubescens stem and leaf contains volatile oil, and composition is australene (α-Pinene), nopinene 0.16～1%, limonene (Limonene) 0.16%, 1.8 cineoles (Cineole) 0.33%, cymol (P-Cymene) 0.16%, king's aldehyde (Nonaldehyde) 1.33%, capraldehyde (Decanal) 1%b-, beta-elemene (β-Elemene) 20.23%, a Palmic acid (Palmatic acid) 6.6% in the oil.Also obtain two kinds of diterpene: rubescensine A (Oridinin), second element (Ponicidin), the third plain C
20H
26O
6, the plain C of fourth
20H
30O
6, oneself plain, penta plain C
23H
32O
6, heptan element, hot element and α-Amyrin (α-Amyrin) and five unknown structure compositions.In addition, root, stem and Ye Shang contain trace elements iron, zinc, manganese, copper, chromium, nickel, cobalt, molybdenum, selenium etc.
Chinese invention patent and patent application CN94110281.4,95100286.4,95113606.2,95112013.1,97121836.6,98111550.0,0113767.3,01115446.2,02125611.x relate to antitumor Chinese medicine, wherein comprise Rabdosia rubescens; Chinese invention patent application CN03118782.x relates to antiinflammatory, antiviral Chinese medicine, wherein also comprises Rabdosia rubescens.Yet what these patent applications disclosed all is some compound recipe prescriptions, and none mentions the anti-AIDS toxic action of Rabdosia rubescens, and more none discloses the active site of anti AIDS virus.
The present inventor is research by experiment once, extracts the crude extract of the anti-HIV of Rabdosia rubescens.With the Rabdosia rubescens powder with alcohol reflux or soaking at room temperature, low-speed centrifugal gained precipitation again through water carry with ethanol precipitation after make crude extract DBSHH and DBSHE.Both all have external HIV (human immunodeficiency virus)-resistant activity, are good with DBSHH.With gel chromatography column Sephadex-G75 DBSHH is obtained DBSHH-1, DBSHH-2, DBSHH-3 and DBSHH-4 further the separation, HIV (human immunodeficiency virus)-resistant activity is good (CN200410017625.5) with DBSHH-2.
Summary of the invention
The purpose of this invention is to provide and have the active Rabdosia rubescens extract of anti AIDS virus (DBS).
Second purpose of the present invention provides the application of Rabdosia rubescens extract on the preparation anti-AIDS drug.
The Rabdosia rubescens extract of anti AIDS virus provided by the invention comprises polysaccharide effective site, described polysaccharide effective site is the detanning matter part of Rabdosia rubescens water extracting alcohol hypostasis, and described polysaccharide effective site does not have uv absorption, and iodine is not developed the color, insoluble in methanol and the acetone, the Molish reaction is aubergine.
Described polysaccharide effective site is the ethanol extract of Rabdosia rubescens water extracting alcohol hypostasis detanning matter part.
Described ethanol extract is 40%, 60%, 70%, 80% or 90%EtOH precipitation polysaccharide DBS-40, DBS-60, DBS-70, DBS-80, DBS-90.
The DBS-70 polysaccharide obtains the DBS-70-6 polysaccharide through the dialysis of 36DM bag filter in the described ethanol extract, and its mean molecule quantity is 7900, contains four kinds of monosaccharide: rhamnose, and arabinose, galactose and glucose, the mol ratio between them is 1.0: 2.2: 1.4: 1.0.
The preparation method of described polysaccharide effective site is that DBS water extracting alcohol hypostasis is dissolved in the water, and reuse gelatin solution precipitation is sloughed tannin fully, obtains settled solution.
Described DBS detanning matter is that 40%, 60%, 70%, 80%, 90% ethanol precipitation obtains precipitating polysaccharide DBS-40, DBS-60, DBS-70, DBS-80, DBS-90 with final concentration partly.
Described DBS-70 polysaccharide after lyophilization, obtains the DBS-70-6 polysaccharide again with 36DM bag filter dialysis 72 hours.
Description of drawings
Fig. 1 is the chromatogram of polysaccharide DBS-70-6 molecular weight determination.
Fig. 2 is the gas chromatographic analysis figure of polysaccharide DBS-70-6.
The specific embodiment
The present invention is further elaborated for following embodiment, but these embodiment have any restriction to the present invention absolutely not.Any change that those skilled in the art are done in to the invention process under the enlightenment of this description all will drop in the scope of claims.
The preparation of embodiment 1 Rabdosia rubescens extract
DBS water extracting alcohol hypostasis 169 grams add the 2000ml water dissolution, add 400ml gelatin solution (the 3.2g gelatin is dissolved in the 600ml water and forms solution).Standing over night makes it precipitation fully.The centrifugal precipitation that discards obtains transparent settled solution.The clear liquor that takes a morsel drips gelatin solution if not having precipitation produces, and illustrate that polyphenols precipitation such as tannin is complete.
The cell toxicity test of embodiment 2 Rabdosia rubescens extracts
In one 96 well culture plates, with prepared product, i.e. embodiment 1 gained clear liquor serial dilution, per three holes are a sample, add an amount of laboratory T-cell strain MT-2 then.At CO
2Incubator is cultivated after 3 days for 37 ℃, and pair cell dyes, and measures the OD value, converts to or the cells survival percentage rate through ocr software.If vegetation thing toxicity is very strong, the then whole or big portion of cell meeting death, living cells existence percentage rate is zero or very low; Otherwise, prepared product avirulence or hypotoxicity, living cells existence percentage rate is then near 100 or very high.See Table 1.
Table 1
| Sample concentration (μ g/ml) | Survival rate (%) |
| 480 | 64 |
| 240 | 88 |
| 120 | 90 |
| 60 | 95 |
| 30 | 106 |
| 15 | 94 |
| 7.5 | 74 |
| 3.75 | 64 |
The experiment of embodiment 3 Rabdosia rubescens extract anti AIDS virus
In one 96 well culture plates,, select the prepared product initial concentration to make serial dilution according to the result of embodiment 2 gained.The laboratory acquired immune deficiency syndrome (AIDS) strain (HIV-IIIB) and cell strain MT-2 that add an amount of titre.At CO
2Incubator is cultivated after about 6 days for 37 ℃, and pair cell dyes, and surveys the OD value, converts the non-infected cells percentage rate to through ocr software.If prepared product is to viral unrestraint effect, then infected cells finally becomes multinucleated giant cell and the death of breaking (syncytium); If any antivirus action, non-infected cells survival is in various degree arranged then.With the prepared product concentration that has 50% non-infected cells is valid density.See Table 2.
Table 2
| DBS-A | DBS-B | ||
| Sample concentration (μ g/ml) | Survival rate (%) | Sample concentration (μ g/ml) | Survival rate (%) |
| 100 | 61 | 100 | 70 |
| 50 | 62 | 50 | 67 |
| 25 | 76 | 25 | 71 |
| 12.5 | 90 | 12.5 | 48 |
| 6.25 | 86 | 6.25 | 51 |
| 3.125 | 89 | 3.125 | 27 |
| 1.5625 | 80 | 1.5625 | 14 |
| 0.78 | 52 | 0.78 | 3 |
Through above-mentioned anti-HIV screening, embodiment 1 is extract obtained to be the effective site of anti AIDS virus.This position ultraviolet does not have absorption, and iodine is not developed the color, and is insoluble in methanol and the acetone, and the Molish reaction is aubergine, is shown as compound of polysaccharide.
The initial gross separation of embodiment 4 Rabdosia rubescens extracts
Through Sepabead SP825 macroporous resin Rabdosia rubescens extract is carried out initial gross separation, eluent is followed successively by water, 10%EtOH, 20%EtOH, 30%EtOH, 50%EtOH, thereby obtains five eluting stream parts.
The cell toxicity test of embodiment 5 Rabdosia rubescens extract eluting stream part
Present embodiment carries out with reference to the step of embodiment 2, and wherein prepared product is five eluting stream parts of embodiment 4 gained.
The anti AIDS virus experiment of embodiment 6 Rabdosia rubescens extract eluting stream part
Present embodiment carries out with reference to the step of embodiment 3, and wherein the prepared product Cmax is the Cmax of embodiment 5 gained.
Test HIV (human immunodeficiency virus)-resistant activity respectively, the result shows that five eluting of embodiment 4 gained flow part and all are positive, and antivirus action does not show notable difference.The anti-HIV effect of this explanation DBS compound of polysaccharide is not to be caused by wherein a certain class polysaccharide, but whole polysaccharide all has the effect of this respect.See Table 3.
Table 3
| DBS-5-1 | DBS-5-4 | DBS-5-7 | DBS-5-11 | ||||
| Sample concentration (μ g/ml) | Survival rate (%) | Sample concentration (μ g/ml) | Survival rate (%) | Sample concentration (μ g/ml) | Survival rate (%) | Sample concentration (μ g/ml) | Survival rate (%) |
| 240 | 76 | 250 | 63 | 240 | 78 | 260 | 83 |
| 120 | 91 | 125 | 78 | 120 | 74 | 130 | 73 |
| 60 | 93 | 62.5 | 96 | 60 | 95 | 65 | 94 |
| 30 | 87 | 31.25 | 101 | 30 | 97 | 32.5 | 85 |
| 15 | 21 | 15.63 | 88 | 15 | 101 | 16.25 | 58 |
| 7.5 | 3 | 7.813 | 19 | 7.5 | 77 | 8.125 | 21 |
| 3.75 | 2 | 3.906 | 57 | 3.75 | 39 | 4.063 | 6 |
| 1.875 | 0 | 1.953 | 88 | 1.875 | 41 | 2.031 | 38 |
The purification of embodiment 7 Rabdosia rubescens extracts
DBS detanning matter part (polysaccharide) is dissolved fully with suitable quantity of water, add dehydrated alcohol, making alcoholic acid final concentration is 40%, and the part polysaccharide precipitates, and it is centrifugal, gained precipitation called after crude polysaccharides DBS-40, supernatant quantitatively adds dehydrated alcohol, and making alcoholic acid final concentration is 60%, has the part polysaccharide to precipitate again, it is centrifugal, obtain crude polysaccharides DBS-60; With method obtain 70%, 80% respectively, 90%EtOH precipitation polysaccharide DBS-70, DBS-80, DBS-90.
Through the HIV (human immunodeficiency virus)-resistant activity test, show that DBS-40, DBS-60, DBS-70, DBS-80, DBS-90 all present antivirus action.
The dialysis of embodiment 8 DBS compound of polysaccharide
According to the result of embodiment 2, consider from the operability and the experiment difficulty of experiment, select DBS-70, DBS-90 are carried out dialysis treatment.Adopt 72 hours (dialysis buffer liquid is tap water) of 36DM dialysis band (available from Chemical Reagent Co., Ltd., Sinopharm Group, 20050907) dialysis, remove small-molecule substance.After the DBS-90 dialysis, do not have remaining in the bag filter; After the DBS-70 dialysis, remnants are arranged in the bag filter,, obtain the comparatively pure polysaccharide component of DBS-70-6 its lyophilization.
The molecular weight determination of embodiment 9 DBS compound of polysaccharide DBS-70-6
According to the result of embodiment 3, adopt HP GPC method to measure, with 0.1M KH
2PO
4As mobile phase, sample size is 40 μ l, and the standard dextran is as standard substance, and molecular weight is respectively 21400,84400,133800,2000000.To its retention time mapping on post, obtain standard curve: y=-0.4109x+8.8121 (R by the logarithm of the molecular weight of standard substance
2=0.9999), measure the retention time of DBS compound of polysaccharide DBS-70-6 on post simultaneously, the result shows that retention time is 11.952 minutes.According to standard curve, retention time is 11.952 minutes thus, and converting and obtaining DBS compound of polysaccharide molecular weight is 7900.
The composition of embodiment 10 polysaccharide DBS-70-6
Take by weighing the 10mg sample in test tube; add 3ml 2M trifluoroacetic acid, fill tube sealing behind the nitrogen, 120 ℃ of hydrolysis 2h; after concentrating under reduced pressure removes TFA; water-soluble, add the 25mg sodium borohydride under the room temperature, reduction 4h; add the glacial acetic acid neutralization; reuse glacial acetic acid-methanol (1: 9) mixed liquor repeated multiple times boils off the boric acid of generation, and the gained powder uses acetic anhydride in 110 ℃ of acetylation 2h after intensive drying.Then through gas chromatographic analysis (Shimadzu QP-5050-A type gas phase instrument, 5%OV225/AW-DMC-Chromosorb W packed column) its composition, detect four kinds of monosaccharide, it is rhamnose, arabinose, galactose and glucose, the mol ratio between them are 1.0: 2.2: 1.4: 1.0, and the alduronic acid reaction is negative.
Fig. 1 and Fig. 2 show gas chromatograph results.Wherein:
| Peak number | Peak area % | |
| 1 | 0.15 | |
| 2 | 0.33 | Arabinose |
| 3 | 0.21 | Galactose |
| 4 | 0.15 | Glucose |
Claims (5)
1. the Rabdosia rubescens extract of anti AIDS virus comprises polysaccharide effective site, and described polysaccharide effective site is the detanning matter part of Rabdosia rubescens water extracting alcohol hypostasis, described polysaccharide effective site does not have uv absorption, iodine is not developed the color, and insoluble in methanol and the acetone, the Molish reaction is aubergine.
2. Rabdosia rubescens extract as claimed in claim 1, wherein said polysaccharide effective site are the ethanol extract of Rabdosia rubescens water extracting alcohol hypostasis detanning matter part.
3. Rabdosia rubescens extract as claimed in claim 2, wherein said polysaccharide effective site are 40%, 60%, 70%, 80% or 90%EtOH precipitation polysaccharide DBS-40, DBS-60, DBS-70, DBS-80, DBS-90.
4. Rabdosia rubescens extract as claimed in claim 3, wherein said polysaccharide effective site is the DBS-70-6 polysaccharide of DBS-70 polysaccharide through 36DM bag filter dialysis gained, its mean molecule quantity is 7900, contain four kinds of monosaccharide: rhamnose, arabinose, galactose and glucose, the mol ratio between them are 1.0: 2.2: 1.4: 1.0.
5. the application of the described Rabdosia rubescens extract of claim 1 on the preparation anti-AIDS drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610025274 CN101045079A (en) | 2006-03-30 | 2006-03-30 | Extractive of Rabdosia rubescens having anti AIDS virus function and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610025274 CN101045079A (en) | 2006-03-30 | 2006-03-30 | Extractive of Rabdosia rubescens having anti AIDS virus function and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101045079A true CN101045079A (en) | 2007-10-03 |
Family
ID=38770181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610025274 Pending CN101045079A (en) | 2006-03-30 | 2006-03-30 | Extractive of Rabdosia rubescens having anti AIDS virus function and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101045079A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108373411A (en) * | 2017-12-16 | 2018-08-07 | 山东新华制药股份有限公司 | The preparation method of high-purity 4- chloro-3-hydroxyl ethyl butyrates |
| CN111153972A (en) * | 2018-11-07 | 2020-05-15 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS10-1, and preparation method and application thereof |
| CN111153971A (en) * | 2018-11-07 | 2020-05-15 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS5-1, and preparation method and application thereof |
-
2006
- 2006-03-30 CN CN 200610025274 patent/CN101045079A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108373411A (en) * | 2017-12-16 | 2018-08-07 | 山东新华制药股份有限公司 | The preparation method of high-purity 4- chloro-3-hydroxyl ethyl butyrates |
| CN111153972A (en) * | 2018-11-07 | 2020-05-15 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS10-1, and preparation method and application thereof |
| CN111153971A (en) * | 2018-11-07 | 2020-05-15 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS5-1, and preparation method and application thereof |
| CN111153971B (en) * | 2018-11-07 | 2023-04-07 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS5-1, and preparation method and application thereof |
| CN111153972B (en) * | 2018-11-07 | 2023-04-07 | 上海医药集团股份有限公司 | Isodon glaucocalyx glycoprotein XPS10-1, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum | |
| Mishra et al. | Phcog rev.: Plant review Andrographis paniculata (Kalmegh): A review | |
| Dwevedi et al. | Exploration of phytochemicals found in Terminalia sp. and their antiretroviral activities | |
| Yadav et al. | Strychnos potatorum: Phytochemical and pharmacological review | |
| US6787165B2 (en) | Composition comprising extracts of flos lonicerae, fructus forsythiae and radix scutellariae, uses and preparation thereof | |
| US20060110468A1 (en) | Herbal formulations for arthritis | |
| JP4537849B2 (en) | Echinacea angstifolia extract | |
| Bone | Echinacea: what makes it work | |
| Mehta et al. | A fresh look on bergenin: vision of its novel drug delivery systems and pharmacological activities | |
| CN100525823C (en) | Application of extractive of Daliangjiang, and application in medication | |
| CN101045079A (en) | Extractive of Rabdosia rubescens having anti AIDS virus function and its application | |
| Dube et al. | Review of the traditional uses, Phytochemistry, and pharmacological activities of Rhoicissus Species (Vitaceae) | |
| Oladimeji et al. | The potential therapeutic advantage of Abrus precatorius Linn. an alternative to Glycyrrhiza glabra: a review | |
| Do Nascimento et al. | A Review of the Phytochemistry and Pharmacological Properties of the Genus Arrabidaea | |
| Das et al. | Ethnomedicinal values of Boerhaavia diffusa L. as a panacea against multiple human ailments: a state of art review | |
| KR100988877B1 (en) | Anti-hepatitis B virus agent from Paeonia lactiflora | |
| Constantin et al. | Epilobium sp.(Willow Herb): micropropagation and production of secondary metabolites | |
| Dawada et al. | Hepatoprotective activity of Cassia fistula root against carbon tetrachloride-induced hepatic injury in rats (Wistar) | |
| Mishra et al. | Cordicepssinensis: the Chinese Rasayan-current research scenario | |
| Debenedetti et al. | In vitro antiplasmodial activity of extracts of Argentinian plants | |
| CN1680568B (en) | Microbiological coverting product of curcumenol, use and preparation thereof | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| EP1357924A1 (en) | Antiviral composition made from medicinal plants for combating hiv/aids | |
| CN1682774A (en) | Use of rabdosia and its extract in preparing anti-AIDS medicine | |
| Abudayeh et al. | Bryonia alba L.-a prospective medicinal plant of the Cucurbitaceae family |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |